Eris Lifesciences · NSE: ERIS · BSE: 540596
Q2 FY21 results · Jul–Sep 2020
Eris Lifesciences reported revenue from operations of ₹329.99 crore (up 15.9% from Q2 FY20) and net profit of ₹107.72 crore (up 16.2% from Q2 FY20) for Q2 FY21 (Jul–Sep 2020), on a consolidated basis.
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 329.99 | 284.79 | +15.9% | 293.24 | +12.5% |
| Other income | 2.08 | 5.17 | −59.7% | 1.34 | +55.6% |
| Total income | 332.08 | 289.96 | +14.5% | 294.58 | +12.7% |
| Profit before tax | 115.84 | 102.77 | +12.7% | 94.64 | +22.4% |
| Net profit for the period | 107.72 | 92.71 | +16.2% | 89.02 | +21.0% |
| EPS, basic (₹) | 7.93 | 6.74 | +17.7% | 6.56 | +20.9% |
| Net margin (%) | 32.6 | 32.6 | 30.4 |
| Item | Q2 FY21 | Q2 FY20 | YoY | Q1 FY21 | QoQ |
|---|---|---|---|---|---|
| Revenue from operations | 303.37 | 272.90 | +11.2% | 261.48 | +16.0% |
| Other income | 2.41 | 4.90 | −50.8% | 1.41 | +70.9% |
| Total income | 305.78 | 277.80 | +10.1% | 262.89 | +16.3% |
| Profit before tax | 112.94 | 101.33 | +11.5% | 92.16 | +22.5% |
| Net profit for the period | 105.49 | 91.53 | +15.3% | 87.13 | +21.1% |
| EPS, basic (₹) | 7.77 | 6.66 | +16.7% | 6.42 | +21.0% |
| Net margin (%) | 34.8 | 33.5 | 33.3 |
Consolidated
- Filed with BSE
- 05 Nov 2020, 13:15 IST
- Board meeting
- 03 Nov 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE
Standalone
- Filed with BSE
- 05 Nov 2020, 13:15 IST
- Board meeting
- 03 Nov 2020
- Period
- 01 Jul 2020 to 30 Sep 2020
- Review status
- Unaudited
- Source
- XBRL filing on BSE